Advertisement

Tumor Biology

, Volume 37, Issue 4, pp 5231–5237 | Cite as

Evaluation of prognostic factors in localized high-grade undifferentiated pleomorphic sarcoma: report of a multi-institutional experience of Anatolian Society of Medical Oncology

  • Melike Ozcelik
  • Mesut Seker
  • Emrah Eraslan
  • Sinan Koca
  • Dogan Yazilitas
  • Ozlem Ercelep
  • Ersin Ozaslan
  • Serap Kaya
  • Ilhan Hacibekiroglu
  • Serkan Menekse
  • Asude Aksoy
  • Burcu Yapar Taskoylu
  • Umut Varol
  • Erkan Arpaci
  • Aydin Ciltas
  • Berna Oksuzoglu
  • Nurullah Zengin
  • Mahmut Gumus
  • Mehmet Aliustaoglu
Original Article
  • 172 Downloads

Abstract

Most data on prognostic factors for patients with high-grade undifferentiated pleomorphic sarcoma (HGUPS) is obtained from analyses of soft tissue sarcomas. The purpose of this study was to evaluate the clinicopathologic features and their impact on outcomes specifically in patients diagnosed with HGUPS. In this multicenter trial, we retrospectively analyzed 112 patients who were diagnosed and treated at 12 different institutions in Turkey. We collected data concerning the patients, tumor characteristics, and treatment modalities. There were 69 males (61.6 %) and 43 females (38.4 %). Median age was 56 years (19–90). The most common anatomic site of tumor origin was the upper extremity. Pleomorphic variant was the predominant histological subtype. Median tumor size was 8.2 cm (0.6–30 cm). Tumors were mainly deeply seated (57.1 %). Fifty-seven patients (50.9 %) were stage II and the remainder were stage III at the time of diagnosis. Median follow-up was 30 months (2–160). The primary site of distant metastasis was the lung (73.5 %) and the second most common site was the liver (11.7 %). The 5-year overall survival, distant metastasis-free survival, and local recurrence-free survival rates were 56.3, 53.4, and 67.2 %, respectively. Multivariate analysis showed that Eastern Cooperative Oncology Group (ECOG) performance score of II (p = 0.033), deep tumor location (p = 0.000), and development of distant metastasis (p = 0.004) were negatively correlated with overall survival, and perioperative radiotherapy and negative microscopic margins were significant factors for local control rates (p = 0.000 for each). Deep tumor location (p = 0.003) was the only adverse factor related to distant metastasis-free survival. Deep tumor location, ECOG performance score of II, and development of distant metastasis carry a poor prognostic implication on overall survival. These will aid clinicians in predicting survival and treatment decision.

Keywords

High-grade undifferentiated pleomorphic sarcoma Malignant fibrous histiocytoma Prognostic factors Soft tissue sarcoma 

Notes

Acknowledgments

None.

Compliance with ethical standards

Conflicts of interest

None

References

  1. 1.
    O’Brien JE, Stout AP. Malignant fibrous xanthomas. Cancer. 1964;17:1445–55.CrossRefPubMedGoogle Scholar
  2. 2.
    Dei Tos AP. Classification of pleomorphic sarcomas: where are we now? Histopathology. 2006;48:51–62.CrossRefPubMedGoogle Scholar
  3. 3.
    Massi D, Beltrami G, Capanna R, Franchi A. Histopathological re-classification of extremity pleomorphic soft tissue sarcoma has clinical relevance. Eur J Surg Oncol. 2004;30:1131–6.CrossRefPubMedGoogle Scholar
  4. 4.
    Fletcher CD. The evolving classification of soft tissue tumours: an update based on the new WHO classification. Histopathology. 2006;48:3–12.CrossRefPubMedGoogle Scholar
  5. 5.
    Kearney MM, Soule EH, Ivins JC. Malignant fibrous histiocytoma: a retrospective study of 167 cases. Cancer. 1980;45:167–78.CrossRefPubMedGoogle Scholar
  6. 6.
    Weiss SW, Enzinger FM. Malignant fibrous histiocytoma: an analysis of 200 cases. Cancer. 1978;41:2250–66.CrossRefPubMedGoogle Scholar
  7. 7.
    Leite C, Goodwin JW, Sinkovics JG, Baker LH, Benjamen R. Chemotherapy of malignant fibrous histiocytoma. A Southwest Oncology Group Report. Cancer. 1977;40:2010–14.CrossRefPubMedGoogle Scholar
  8. 8.
    Zagars GK, Ballo MT, Pisters PW, Pollock RE, Patel SR, Benjamin RS, et al. Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy: an analysis of 1225 patients. Cancer. 2003;97(10):2530–43.CrossRefPubMedGoogle Scholar
  9. 9.
    Coindre JM, Terrier P, Guillou L, Le Doussal V, Collin F, Ranchere D, et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer. 2001;91(10):1914–26.CrossRefPubMedGoogle Scholar
  10. 10.
    Toulmonde M, Le Cesne A, Mendiboure J, Blay JY, Piperno-Neumann S, Chevreau C, et al. Long-term recurrence of soft tissue sarcomas: prognostic factors and implications for prolonged follow-up. Cancer. 2014;120(19):3003–6.CrossRefPubMedGoogle Scholar
  11. 11.
    Maretty-Nielsen K, Aggerholm-Pedersen N, Safwat A, Jørgensen PH, Hansen BH, Baerentzen S, et al. Prognostic factors for local recurrence and mortality in adult soft tissue sarcoma of the extremities and trunk wall: a cohort study of 922 consecutive patients. Acta Orthop. 2014;85(3):323–32.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Salcedo Hernández RA, Lino-Silva LS, de León DC, Herrera-Gómez Á, Martinez-Said H, Meneses-Garcia A. Importance of tumor size in soft tissue sarcomas: a proposal for a nomogram based on a score system to staging soft tissue sarcomas in the postoperative setting. Med Oncol. 2014;31(3):873.CrossRefPubMedGoogle Scholar
  13. 13.
    Jones NB, Iwenofu H, Scharschmidt T, Kraybill W. Prognostic factors and staging for soft tissue sarcomas: an update. Surg Oncol Clin N Am. 2012;21(2):187–200.CrossRefPubMedGoogle Scholar
  14. 14.
    Kempson RL, Kyriakos M. Fibroxanthosarcoma of the soft tissues—a type of malignant fibrous histiocytoma. Cancer. 1972;29:961–76.CrossRefPubMedGoogle Scholar
  15. 15.
    Weiss SW, Enzinger FM. Myxoid variant of malignant fibrous histiocytoma. Cancer. 1977;39:1672–85.CrossRefPubMedGoogle Scholar
  16. 16.
    Le Doussal V, Coindre JM, Leroux A, Hacene K, Terrier P, Bui NB, et al. Prognostic factors for patients with localized primary malignant fibrous histiocytoma: a multicenter study of 216 patients with multivariate analysis. Cancer. 1996;77(9):1823–30.CrossRefPubMedGoogle Scholar
  17. 17.
    Rööser B, Willén H, Gustafson P, Alvegård TA, Rydholm A. Malignant fibrous histiocytoma of soft tissue: a population-based epidemiologic and prognostic study of 137 patients. Cancer. 1991;67:499–505.CrossRefPubMedGoogle Scholar
  18. 18.
    Oda Y, Tamiya S, Oshiro Y, Hachitanda Y, Kinukawa N, Iwamoto Y, et al. Reassessment and clinicopathological prognostic factors of malignant fibrous histiocytoma of soft parts. Pathol Int. 2002;52(9):595–606.CrossRefPubMedGoogle Scholar
  19. 19.
    Pezzi CM, Rawlings MS, Esgro JJ, Pollock RE. Prognostic factors in 227 patients with malignant fibrous histiocytoma. Cancer. 1992;69:2098–103.CrossRefPubMedGoogle Scholar
  20. 20.
    Belal A, Kandil A, Allam A, Khafaga Y. Malignant fibrous histiocytoma: a retrospective study of 109 cases. Am J Clin Oncol. 2002;25:16–22.CrossRefPubMedGoogle Scholar
  21. 21.
    Engellau J, Persson A, Bendahl PO, Akerman M, Domanski HA, Bjerkehagen B, et al. Expression profiling using tissue microarray in 211 malignant fibrous histiocytomas confirms the prognostic value of Ki-67. Virchows Arch. 2004;445(3):224–30.CrossRefPubMedGoogle Scholar
  22. 22.
    Vasileios KA, Eward WC, Brigman BE. Surgical treatment and prognosis in patients with high-grade soft tissue malignant fibrous histiocytoma of the extremities. Arch Orthop Trauma Surg. 2012;132(7):955–61.CrossRefPubMedGoogle Scholar
  23. 23.
    Hsu HC, Huang EY, Wang CJ. Treatment results and prognostic factors in patients with malignant fibrous histiocytoma. Acta Oncol. 2004;43(6):530–5.CrossRefPubMedGoogle Scholar
  24. 24.
    Li GX, Guo W. Analysis of therapeutic strategies and prognostic factors of malignant fibrous histiocytoma of soft tissue. Zhonghua Wai Ke Za Zhi. 2011;49(11):974–7.PubMedGoogle Scholar
  25. 25.
    Kim MS, Cho WH, Song WS, Lee SY, Jeon DG. Prognostic significance of ezrin expression in pleomorphic malignant fibrous histiocytoma. Anticancer Res. 2007;27:1171–8.PubMedGoogle Scholar
  26. 26.
    Lehnhardt M, Daigeler A, Homann HH, Schwaiberger V, Goertz O, Kuhnen C, et al. MFH revisited: outcome after surgical treatment of undifferentiated pleomorphic or not otherwise specified (NOS) sarcomas of the extremities—an analysis of 140 patients. Langenbecks Arch Surg. 2009;394(2):313–20.CrossRefPubMedGoogle Scholar
  27. 27.
    Antman KH. Adjuvant therapy of sarcomas of soft tissue. Semin Oncol. 1997;24(5):556–60.PubMedGoogle Scholar
  28. 28.
    Frustaci S, Gherlinzoni F, De Paoli A, Bonetti M, Azzarelli A, Comandone A, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol. 2001;19(5):1238–47.CrossRefPubMedGoogle Scholar
  29. 29.
    Pervaiz N, Colterjohn N, Farrokhyar F, Tozer R, Figueredo A, Ghert M. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008;113(3):573–81.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Melike Ozcelik
    • 1
  • Mesut Seker
    • 2
  • Emrah Eraslan
    • 3
  • Sinan Koca
    • 4
  • Dogan Yazilitas
    • 5
  • Ozlem Ercelep
    • 1
  • Ersin Ozaslan
    • 6
  • Serap Kaya
    • 4
  • Ilhan Hacibekiroglu
    • 7
  • Serkan Menekse
    • 8
  • Asude Aksoy
    • 9
  • Burcu Yapar Taskoylu
    • 10
  • Umut Varol
    • 11
  • Erkan Arpaci
    • 12
  • Aydin Ciltas
    • 13
  • Berna Oksuzoglu
    • 3
  • Nurullah Zengin
    • 5
  • Mahmut Gumus
    • 2
  • Mehmet Aliustaoglu
    • 1
  1. 1.Department of Medical OncologyKartal Dr. Lutfi Kirdar Education and Research HospitalIstanbulTurkey
  2. 2.Department of Medical OncologyBezmialem Vakif University School of MedicineIstanbulTurkey
  3. 3.Department of Medical OncologyAnkara Oncology Education and Research HospitalAnkaraTurkey
  4. 4.Department of Medical OncologyMarmara University Pendik Education and Research HospitalIstanbulTurkey
  5. 5.Department of Medical OncologyAnkara Numune Education and Research HospitalAnkaraTurkey
  6. 6.Department of Medical OncologyErciyes University School of MedicineKayseriTurkey
  7. 7.Department of Medical OncologyTrakya University School of MedicineEdirneTurkey
  8. 8.Department of Medical OncologyCelal Bayar University School of MedicineManisaTurkey
  9. 9.Department of Medical OncologyInonu University School of MedicineMalatyaTurkey
  10. 10.Department of Medical OncologyPamukkale University School of MedicineDenizliTurkey
  11. 11.Department of Medical OncologyIzmir Katip Celebi University Atatürk Education and Research HospitalIzmirTurkey
  12. 12.Department of Medical OncologySakarya University School of MedicineSakaryaTurkey
  13. 13.Department of Medical OncologyOrdu University School of MedicineOrduTurkey

Personalised recommendations